Effect of carbogen breathing on the radiation response of a human glioblastoma xenograft: Analysis of hypoxia and vascular parameters of regrowing tumors

Strahlentherapie und Onkologie

Volumn 182, Issue 7, 2006, Pages 408-414

  Schuuring, Janneke ^a,b   Bussink, Johan ^a   Bernsen, Hans J J A ^a,c   Peeters, Wenny ^a   Van Der Kogel, Albert J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b GROENE HART HOSPITAL   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

Carbogen; Glioblastoma; Hypoxia; Irradiation; Vascularity

Indexed keywords

CARBOGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CARBOGEN BREATHING; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; OXYGENATION; RADIATION DOSE; RADIATION EXPOSURE; RADIATION RESPONSE; THERAPY; THERAPY EFFECT; TUMOR BLOOD FLOW; TUMOR CELL; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANOXIA; CARBON DIOXIDE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, NUDE; OXYGEN; RADIATION-SENSITIZING AGENTS; TRANSPLANTATION, HETEROLOGOUS;

EID: 33745794880     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-006-1545-5     Document Type: Article

References (47)

1. Al-Hallaq HA, Zamora MA, Fish BL, et al. Using high spectral and spatial resolution bold MRI to choose the optimal oxygenating treatment for individual cancer patients. Adv Exp Med Biol 2003;530:433-40.
2. Begg AC. Principles and practices of the tumor growth delay assay. In: Kallman RF, ed. Rodent tumor models in experimental cancer therapy. Oxford: Pergamon Press, 1987:114-21.
3. Bernsen HJ, Rijken PF, Oostendorp T, et al. Vascularity and perfusion of human gliomas xenografted in the athymic nude mouse. Br J Cancer 1995;71:721-6.
4. Bussink J, Kaanders JH, Rijken PF, et al. Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: effects of carbogen and nicotinamide. Radiother Oncol 1999;50:173-84.
5. Bussink J, Kaanders JH, Rijken PF, et al. Changes in blood perfusion and hypoxia after irradiation of a human squamous cell carcinoma xenograft tumor line. Radiat Res 2000;153:398-404.
6. Bussink J, Kaanders JH, Strik A, et al. Effects of nicotinamide and carbogen on oxygenation in human tumor xenografts measured with luminescense-based fiber-optic probes. Radiother Oncol 2000;57:21-30.
7. Combs SE, Gutwein S, Schulz-Ertner D, et al. Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. Strahlenther Onkol 2005;181:372-7.
8. Dewhirst MW, Oliver R, Tso CY, et al. Heterogeneity in tumor microvascular response to radiation. Int J Radiat Oncol Biol Phys 1990;18:559-68.
9. Dunn JF, O'Hara JA, Zaim-Wadghiri Y, et al. Changes in oxygenation of intracranial tumors with carbogen: a BOLD MRI and EPR oximetry study. J Magn Reson Imaging 2002;16:511-21.
10. Elas M, Williams BB, Parasca A, et al. Quantitative tumor oxymetric images from 4D electron paramagnetic resonance imaging (EPRI): methodology and comparison with blood oxygen level-dependent (BOLD) MRI. Magn Reson Med 2003;49:682-91.
11. Evans SM, Judy KD, Dunphy I, et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004;10:8177-84.
12. Fatigante L, Ducci F, Cartei F, et al. Carbogen and nicotinamide combined with unconventional radiotherapy in glioblastoma multiforme: a new modality treatment. Int J Radiat Oncol Biol Phys 1997;37:499-504.
13. Fertil B, Malaise EP. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys 1985;11:1699-707.
14. Gilbert MR, Loghin M. The treatment of malignant gliomas. Curr Treat Options Neurol 2005;7:293-303.
15. Gray LH, Conger AD, Ebert M, et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638-48.
16. Hoskin PJ, Sibtain A, Daley FM, et al. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer 2003;89:1290-7.
17. Howe FA, Robinson SP, Rodrigues LM, et al. Flow and oxygenation dependent (FLOOD) contrast MR imaging to monitor the response of rat tumors to carbogen breathing. Magn Reson Imaging 1999;17:1307-18.
18. 99mTc-HMPAO SPECT study. Radiother Oncol 1998;48:135-42.
19. Kaanders JH, Pop LA, Marres HA, et al. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. Radiother Oncol 1998;48:115-22.
20. Kaanders JHAM, Pop LA, Marres HA, et al. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;52:769-78.
21. Kleihues P, Cavanee WK. World Health Organization classification of tumours: pathology and genetics: tumours of the nervous system, 2nd edn. Oxford: Oxford University Press, 2000:29-39.
22. Kocher M, Kunze S, Eich HT, et al. Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma. Strahlenther Onkol 2005;181:157-63.
23. Kocher M, Treuer H, Muller RP. Quantification of tumor reoxygenation during accelerated radiation therapy. Radiology 1997;205:263-8.
24. Konerding MA, Malkusch W, Klapthor B, et al. Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts. Br J Cancer 1999;80:724-32.
25. Kruuv JA, Inch WR, McCredie JA. Blood flow and oxygenation of tumors in mice. I. Effects of breathing gases containing carbon dioxide at atmospheric pressure. Cancer 1967;20:51-9.
26. 2) during accelerated radiotherapy of head and neck carcinoma. Eur J Cancer 1998;34:856-61.
27. Lee I, Boucher Y, Jain RK. Nicotinamide can lower tumor interstitial fluid pressure: mechanistic and therapeutic implications. Cancer Res 1992;52:3237-40.
28. Miralbell R, Mornex F, Greiner R, et al. Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933. J Clin Oncol 1999;17:3143-9.
29. Nieder C, Andratschke N, Wiedenmann N, et al. Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome? Strahlenther Onkol 2004;180:401-7.
30. Partridge SE, Aquino-Parsons C, Luo C, et al. A pilot study comparing intratumoral oxygenation using the comet assay following 2.5% and 5% carbogen and 100% oxygen. Int J Radiat Oncol Biol Phys 2001;49:575-80.
31. Peters CE, Chaplin DJ, Hirst DG. Nicotinamide reduces tumour interstitial fluid pressure in a dose- and time-dependent manner. Br J Radiol 1997;70:160-7.
32. Rijken PF, Bernsen HJ, van der Kogel AJ. Application of an image analysis system to the quantisation of tumor perfusion and vascularity in human glioma xenografts. Microvasc Res 1995;50:141-53.
33. Rijpkema M, Schuuring J, Bernsen PL, et al. BOLD MRI response to hypercapnic hyperoxia in patients with meningiomas: correlation with gadolinium-DTPA uptake rate. Magn Reson Imaging 2004;22:761-7.
34. Roberge D, Souhami L. Stereotactic radiosurgery in the management of intracranial gliomas. Technol Cancer Res Treat 2003;2:117-25.
35. Robinson SP, Howe FA, Stubbs M, et al. Effects of nicotinamide and carbogen on tumor oxygenation, blood flow, energetics and blood glucose levels. Br J Cancer 2000;82:2007-14.
36. Robinson SP, Rijken PF, Howe FA, et al. Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry. J Magn Reson Imaging 2003;17:445-54.
37. Rodrigues LM, Howe FA, Griffiths JR, et al. Tumor R2* is a prognostic indicator of acute radiotherapeutic response in rodent tumors. J Magn Reson Imaging 2004;19:482-8.
38. Rojas A. Radiosensitization with normobaric oxygen and carbogen. Radiother Oncol 1991;1:65-70.
39. Schueller P, Micke O, Palkovic S, et al. 12 years' experience with intraoperative radiotherapy (IORT) of malignant gliomas. Strahlenther Onkol 2005;181:500-6.
40. Shibuya M, Ito S, Davis RL, et al. A new method for analyzing the cell kinetics of human brain tumors by double labeling with bromodeoxyuridine in situ and with iododeoxyuridine in vitro. Cancer 1993;71:3109-13.
41. Simon JM, Noel G, Chiras J, et al. Radiotherapy and chemotherapy with or without carbogen and nicotinamide in inoperable biopsy-proven glioblastoma multiforme. Radiother Oncol 2003;67:45-51.
42. Singh D, Banerji AK, Dwarakanath BS, et al. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol 2005;181:507-14.
43. Stüben G, Budach W, Schick KH, et al. A time-saving system for irradiations of experimental tumors. Strahlenther Onkol 1994;170:36-41.
44. Stüben G, Stuschke M, Knuhmann K, et al. The effect of combined nicotinamide and carbogen treatments in human tumour xenografts: oxygenation and tumour control studies. Radiother Oncol 1998;48:143-8.
45. Stupp R, Mason WP, van den Bent MJ, et al., European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
46. Van der Maazen RW, Thijssen HO, Kaanders JH, et al. Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas. Radiother Oncol 1995;35:118-22.
47. Van der Sanden BP, Heerschap A, Hoofd L, et al. Effect of carbogen breathing on the physiological profile of human glioma xenografts. Magn Reson Med 1999;42:490-9.